Ms. Laurie Little reports

VALEANT PHARMACEUTICALS ANNOUNCES RECEIPT OF ANTITRUST CLEARANCE FOR ITS PREVIOUSLY ANNOUNCED ACQUISITION OF SYNERGETICS USA, INC.

The applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) with respect to the previously announced tender offer by Valeant Pharmaceuticals International Inc.'s indirect wholly owned subsidiary, Blue Subsidiary Corp., for all of the outstanding shares of common stock of Synergetics USA Inc. at a price per share of $6.50, net to the holder in cash (less any applicable withholding taxes and without interest), plus one contractual contingent value right per share, which represents the right to receive up to two contingent payments, if any, of up to $1.00 in the aggregate net to the holder in cash (less any applicable withholding taxes and without interest) was granted early termination, effective Oct. 5, 2015, by the U.S. Federal Trade Commission. The waiting period was scheduled to expire at 11:59 p.m. New York time on Oct. 7, 2015. The early termination of the HSR waiting period satisfies one of the conditions to consummate the tender offer. The completion of the tender offer remains subject to certain other conditions as described in the tender offer statement on schedule TO filed by Valeant on Sept. 16, 2015, as amended. Subject to the satisfaction of the other conditions to closing, the transaction is expected to close in the fourth quarter of 2015.

We seek Safe Harbor.